Navigation Links
IDM Pharma Announces Non-Binding Opinion of the European Committee for Medicinal Products for Human Use (CHMP) that Mifamurtide (L-MTP-PE) Provides a Possible Clinical Benefit in Survival
Date:1/25/2008

with the non-binding opinion of the CHMP, whether the European Commission will follow the final opinion of the CHMP once issued, whether the likely timing for the final opinion of the CHMP and the regulatory decision in Europe will occur as expected by the Company, the possibility that the Company may not be able to collect, analyze and submit additional data in an amendment to the NDA for L-MTP-PE within the timeframe expected by the Company, if at all, the possibility that such data will not support the clinical benefit of L-MTP-PE in the treatment of non-metastatic osteosarcoma, will not allow a more robust analysis of L-MTP-PE, will not continue to support its overall survival benefit in osteosarcoma, and may not provide substantial evidence for the potential regulatory approval of L-MTP-PE, the timing of the regulatory agencies' review of the submissions for marketing approval of L-MTP-PE, the ability of the Company to respond to questions raised by the regulatory authorities in a satisfactory manner, the time needed to respond to any issues raised by the regulatory authorities with regard to regulatory submissions for L-MTP-PE, the possibility that regulatory authorities may not consider preclinical and early clinical development work conducted by Ciba-Geigy and efficacy data from the Phase 3 trial conducted by Children's Oncology Group as adequate for their assessment of L-MTP-PE, which may cause delays in review, may result in the regulatory authorities requiring the Company to conduct additional clinical trials, or may result in a determination by the regulatory authorities that the data does not support marketing approval, whether regulatory authorities will approve L-MTP-PE within the time frame expected by the Company or at all, and whether the Company will be able to manufacture and commercialize L-MTP-PE even if it is approved by regulatory authorities. Other risks affecting the Company and its drug development programs include whether the Company or a
'/>"/>
SOURCE IDM Pharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Thomson Scientific Publishes The Ones to Watch - A Quarterly Review of Phase Changes in the Pharmaceutical Pipeline
2. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
5. Clinical Trial Effectiveness: How Pharmas & Biotechs Save Cost with Savvy Investigator Management
6. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
7. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
8. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
9. Par Pharmaceutical Begins Shipment of Additional Dosage Strength of Generic TOPROL-XL(R)
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... Calif. , July 27, 2015 Allergan ... (NASDAQ: KYTH ) today announced that the U.S. ... the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act ... acquisition of KYTHERA.  Logo - http://photos.prnewswire.com/prnh/20150612/222796LOGO ... of Allergan and KYTHERA filed a Pre-Merger Notification and ...
(Date:7/27/2015)... 2015   Mallinckrodt plc (NYSE: ... today that it has entered into a definitive ... contrast media and delivery systems (CMDS) business to ... at approximately $270 million.   Mallinckrodt,s ... with the company,s stated plan to strategically streamline ...
(Date:7/27/2015)... -- EnzymeBioSystems (OTC BB: ENZB - News) announces that a ... the Company,s lead pharmaceutical product. EnzymeBioSystems plans to seek ... prevention of breast cancer. "We are pleased ... has been completed," stated Gary Rojewski , CEO ... will allow us to move forward in beginning to ...
Breaking Medicine Technology:Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 2Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 3Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 4Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 5Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 6Mallinckrodt Enters Agreement To Sell Its Contrast Media And Delivery Systems Imaging Business To Guerbet For $270 Million 7Amooranin Preclinical Sample Batch Completed 2
... Determine How Chest X-Ray CAD Could ... High-Tech Tool for Early Detection, Increased Patient ... and Riverain Medical,today announced the establishment of the ... chest X-ray CAD (computer-aided detection) can improve,practical early ...
... 26 CuraGen Corporation,(Nasdaq: CRGN ), a ... (Copenhagen Stock Exchange: TOPO) announced,today that updated preliminary ... belinostat for T-cell lymphomas, and new preclinical data,evaluating ... presented,at the 2007 American Society of Hematology (ASH) ...
Cached Medicine Technology:Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 2Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 3Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 4Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 5Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 6Cleveland Clinic Leading Clinical Program to Improve Early-Stage Lung Cancer Detection 7CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 2CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 3CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 4CuraGen and TopoTarget Announce Presentations on Belinostat at the Upcoming American Society of Hematology 49th Annual Meeting 5
(Date:7/27/2015)... ... 27, 2015 , ... BESLER Consulting today announced the publication ... for Medicare and Medicaid Services (CMS) provides each hospital affected by the HRRP ... as the QualityNet Hospital-Specific Report (HSR), this report contains a variety of insights ...
(Date:7/27/2015)... NJ (PRWEB) , ... July 27, 2015 , ... Gary ... Jersey. Dr. Breslow is Founder and Medical Director of The Breslow Center in ... the face, breast, and body in Northern New Jersey. The Breslow Center also ...
(Date:7/27/2015)... ... 27, 2015 , ... For a limited time, Huntington Beach dentist , ... is a great time to change up a look or to simply brighten a ... affect your self-esteem. Over time, the enamel coating can become worn and can expose ...
(Date:7/27/2015)... ... 2015 , ... According to an article published by the Times Free ... Tennessee stemming from intravenous drug use. Intravenous drug use causes more overdoses and is ... diseases including Hepatitis B and C and HIV. Drug treatment facilities in Tennessee have ...
(Date:7/27/2015)... ... July 27, 2015 , ... Hexagon ... new way to understand and share your geospatial experience. These new light-weight applications ... to solve distinct business problems. , “Our world is more dynamic than it ...
Breaking Medicine News(10 mins):Health News:BESLER Consulting Publishes E-book Focused on Reducing Hospital Readmissions 2Health News:NJ Top Doc, Dr. Gary Breslow, has launched Zwivel; a New Online Cosmetic Consultation Service for Doctors and Patients 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 2Health News:Huntington Beach Cosmetic Dentist, Dr. Rassouli, is Now Offering a Summer Promotion on Zoom Whitening 3Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 2Health News:Tennessee Sees an Increase in Hepatitis C Infections from Intravenous Heroin Use 3Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 2Health News:Hexagon Geospatial Visualizes Stories with the Hexagon Smart M.App® 3
... disease, experts say, , , THURSDAY, May 21 (HealthDay ... levels also reduce their risk of heart attack ... have been several conflicting reports about the value ... patients in preventing heart attack and heart disease. ...
... Bayer HealthCare Pharmaceuticals, Inc. today announced that ... 73-4506 (DAST-Inhibitor) will be presented at the 45th Annual ... in Orlando, Florida, May 29 - June 2. ... the oral multi-kinase inhibitor BAY 73-4506 is one of ...
... Omnicare, Inc., which calls itself "the nation,s leading ... to settle Medicaid fraud charges by the State ... had committed Medicaid fraud by illegally switching the ... other facilities. Omnicare,s conduct had originally been ...
... New Method for Optimizing Cardiac Resynchronization Therapy During Exercise. The ... difference in treating CRT patients." Dr. Abraham Kocheril, Professor of ... Illinois at Chicago. , ... Minneapolis-St. ...
... A protein that plays a key role in tumor formation, ... that extends lifespan by dietary restriction. The finding, which appears ... PLoS Genetics , provides a new understanding of how ... scientists new targets for developing and testing drugs that could ...
... and lifestyle characteristics can be linked to different invasive ... presented in the open access journal Breast Cancer ... of the condition are associated with different kinds of ... Research, California, led a team of researchers who used ...
Cached Medicine News:Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 2Health News:Strict Blood Sugar Control Lowers Heart Risks in Diabetics 3Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 2Health News:Bayer to Present Data on Development Compound BAY 73-4506 at 45th Annual Meeting of the American Society of Clinical Oncology 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 2Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 3Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 4Health News:National Pharmacy Omnicare Pays 'Unusual' Settlement to Resolve Charges of Generic Drug Switching in Delaware Nursing Homes, Resulting From 'Qui Tam' Lawsuit 5Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 2Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 3Health News:Heart Rhythm Society Introduced to New Method for Optimizing Cardiac Resynchronization Therapy During Exercise 4Health News:Key protein may explain the anti-aging and anti-cancer benefits of dietary restriction 2
3.5v Coaxial Ophthalmoscope Set with Convertible Handle and Hard Case. Our 3.5v Coaxial Ophthalmoscope Sets feature high-quality instruments, handles, and cases....
High-quality eyecare from the preferred name in diagnostic instruments....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Medicine Products: